Cancer Treatment Adaptations in the COVID-19 Era

Waisberg, Federico; Enrico, Diego; Ángel, Martín; Chacón, Matías

doi:10.1200/op.20.00218

Cited by 24 publications

(27 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…De forma particular, el diagnóstico incidental de lesiones tumorales torácicas en pacientes con infección por SARS-CoV-2 supone un desafío adicional, tanto desde el punto de vista diagnóstico como terapéutico. Aunque existen algunas publicaciones que abordan el manejo clínico de los pacientes con cáncer en la pandemia actual de SARS-CoV-2, no existen guías específicas con respecto a la realización de procedimientos de intervencionismo torácico diagnóstico en pacientes con lesiones tumorales y que además están infectados con SARS-CoV-2 [2][3][4][5][6][7][8][9][10][11][12] . Presentamos dos casos en los que se detectaron lesiones tumorales torácicas que requirieron ser biopsiadas, con control radiológico, en el pico de la pandemia de COVID-19 que asolaba Madrid en la segunda quincena de marzo de 2020.…”

Section: Covid-19: Thoracic Diagnostic Interventional Procedures In Tunclassified

COVID-19: intervencionismo diagnóstico torácico en tiempos difíciles

Gorospe

Ayala-Carbonero

Ureña-Vacas

et al. 2020

Archivos de Bronconeumología

View full text Add to dashboard Cite

Section: Covid-19: Thoracic Diagnostic Interventional Procedures In Tunclassified

COVID-19: intervencionismo diagnóstico torácico en tiempos difíciles

Gorospe

Ayala-Carbonero

Ureña-Vacas

et al. 2020

Archivos de Bronconeumología

View full text Add to dashboard Cite

“…Several aspects should be carefully analyzed, including the risk of relapse or disease progression, the estimated endpoints of the therapy, the comorbidities including other patients, and the impact of coronavirus transmission in the local community [113]. In order to meet these requirements, some suggestions can be considered, such as changing therapy regimens and limiting patients' visits to the hospital.…”

Section: Discussionmentioning

confidence: 99%

Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?

et al. 2020

View full text Add to dashboard Cite

Dysregulation of the immune system undoubtedly plays an important and, perhaps, determining role in the COVID-19 pathogenesis. While the main treatment of the COVID-19 intoxication is focused on neutralizing the excessive inflammatory response, it is worth considering an equally significant problem of the immunosuppressive conditions including immuno-paralysis, which lead to the secondary infection. Therefore, choosing a treatment strategy for the immune-mediated complications of coronavirus infection, one has to pass between Scylla and Charybdis, so that, in the fight against the “cytokine storm,” it is vital not to miss the point of the immune silence that turns into immuno-paralysis.

show abstract

“…It is noteworthy, however, that signi cantly more non-survival patients with hematologic malignancies, such as leukemia or lymphoma, in which severe complications such as anemia, thrombocytopenia and profound derangements in coagulation function are inherently more expected. Whether to continue cancer therapy or to delay it is still in controversial, as the risk of cancer progression after stopping cancer therapy remains unknown [3,8]. In general, treatment delay is not recommended in patients who are at high risk of disease progression or patients who are receiving curative cancer therapy despite the potential risk of COVID-19 infection during anticancer therapy [17].…”

Section: Discussionmentioning

confidence: 99%

“…As of this writing, more than 2 million patients are known to have been infected around the world. Thousands of cases have died every day due to lack of adequate medical resources, speci c treatments, and lack of approved vaccine [3].…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics, outcomes and follow-up of COVID-19 infection in cancer patients

Fang¹,

Ling²,

Wu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: The study is to describe the clinical characteristics, outcomes and follow-up of cancer patients with COVID-19. Methods: Clinical records, demographic data, signs and symptoms, laboratory results, cytokine profiles, chest CT scans, comorbidities, treatments, clinical outcomes, and RT-PCR of SARS-CoV-2 after discharge were retrospectively collected for fifty-six cancer patients with laboratory-confirmed COVID-19 pneumonia who were admitted to Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China, from Feb 1 to Apr 1, 2020. Evidence of cytokine profiles were assessed by testing for the IL1β, IL2R, IL6, IL8, IL10, and TNF - α in the peripheral blood of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infected cancer patients. Results: Of 2143 patients with COVID-19, 56 cancer patients were included. The patients were divided into two groups, as cancer survivors, and cancer non-survivors. 12 (21%) patients with lymphopenia (0.5 [0.3-0.7]) had died during hospital stay. In non-survivors, IL2R, IL6, and IL10 were higher. 3(6.8%) cancer survivors with COVID-19 had positive RT-PCR test results again shortly after discharge. Conclusion: The mortality rate of COVID-19 among cancer patients are considerable. Cancer non-survivors are characterized by more severe lymphopenia and a higher levels of cytokines. Recovered cancer survivors still may be virus carriers.

show abstract

Cancer Treatment Adaptations in the COVID-19 Era

Cited by 24 publications

References 18 publications

COVID-19: intervencionismo diagnóstico torácico en tiempos difíciles

COVID-19: intervencionismo diagnóstico torácico en tiempos difíciles

Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?

Clinical characteristics, outcomes and follow-up of COVID-19 infection in cancer patients

Contact Info

Product

Resources

About